Date Title & Summary Additional Formats
November 7, 2022
Certara Reports Third Quarter 2022 Financial Results
Biosimulation software and services fuel third quarter growth PRINCETON, N.J. , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2022 and reiterated its full year guidance.
November 7, 2022
Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase
Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares PRINCETON, N.J. , Nov. 07, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) today announced that Arsenal Capital Partners (“Arsenal”), a
November 2, 2022
Certara to Participate in Upcoming Investor Conferences
PRINCETON, N.J. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Jeffries London Healthcare Conference Date and Time:   Tuesday, November 15 at 4:25PM
October 19, 2022
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Software for Evaluating Regulatory Submissions
The PMDA enters 9th consecutive year of using Certara’s software PRINCETON, N.J. , Oct. 19, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. , (Nasdaq: CERT) a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses
October 13, 2022
Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022
PRINCETON, N.J. , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7 th , 2022.
August 31, 2022
Certara to Participate in Upcoming Investor Conferences
PRINCETON, N.J. , Aug. 31, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: • Morgan Stanley 20 th Annual Global Healthcare Conference   Date and Time:   Tuesday,
August 11, 2022
Certara Announces Secondary Offering
PRINCETON, N.J. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) (“Certara”), a global leader in biosimulation, today announced the sale by certain stockholders (the “Selling Stockholders”), including EQT Avatar Parent L.P. , in an underwritten secondary offering of 7,000,000 shares
August 9, 2022
Certara Reports Second Quarter 2022 Financial Results
Biosimulation software and services fuel second quarter growth PRINCETON, N.J. , Aug. 09, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2022 and adjusted its full year guidance.
August 5, 2022
Certara Introduces Update of Pinnacle 21™ Enterprise and New Pinnacle 21™ Data Exchange Module
New automation, analytics and collaboration features save time and ensure regulatory compliance PRINCETON, N.J. , Aug. 05, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release 5.2.0 of Pinnacle 21 Enterprise, the Company’s
July 28, 2022
Certara Announces Collaboration with Leading Cancer Center to Advance CAR T-cell Therapies
Certara and Memorial Sloan Kettering Cancer Center to develop biosimulation platform for CAR T-cell therapies PRINCETON, N.J. , July 28, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a 2-year collaboration with Memorial Sloan Kettering
Displaying 1 - 10 of 22